Innovative Medicine Backed by the Power of Artificial Intelligence

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology.

About Us

Company’s Approach to Drug Development

Company’s Approach to Drug Development

AI-based Drug Development

Our neuroscience and immuno-oncology programs utilize our AI approach to drug development.

BXCL501

BXCL501 is an investigational, proprietary, orally dissolving, thin film formulation of dexmedetomidine designed for the treatment of agitation and opioid withdrawal symptoms.

BXCL701

BXCL701 is an investigational, orally-administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

Latest News

BioXcel Therapeutics to Host Virtual Commercial Day on June 25, 2021

View Release

BioXcel Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

View Release

BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II

View Release
View all news

Sign up for Email Alerts

Email Sign Up

Stock Information

BioXcel Therapeutics, Inc.

View Investor Relations View Investor Presentation